DTIL Stock Overview
An advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Precision BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$13.08 |
| 52 Week High | US$27.02 |
| 52 Week Low | US$8.25 |
| Beta | 1.61 |
| 1 Month Change | 35.12% |
| 3 Month Change | 7.48% |
| 1 Year Change | -46.52% |
| 3 Year Change | -95.97% |
| 5 Year Change | -96.76% |
| Change since IPO | -97.50% |
Recent News & Updates
Recent updates
Analysts Just Made A Meaningful Upgrade To Their Precision BioSciences, Inc. (NASDAQ:DTIL) Forecasts
Aug 06
It's Down 29% But Precision BioSciences, Inc. (NASDAQ:DTIL) Could Be Riskier Than It Looks
Jun 23Is Precision BioSciences (NASDAQ:DTIL) Using Debt In A Risky Way?
Mar 14Is Precision BioSciences (NASDAQ:DTIL) Weighed On By Its Debt Load?
Dec 08Precision BioSciences appoints chief business officer from within ranks, rejigs co-founders' roles
Sep 02Precision BioSciences: CAR T Data Updates End Of 2022 And Plenty Of Cash
Aug 16Precision BioSciences Q2 2022 Earnings Preview
Aug 05Precision Bio: Another CAR-T Laggard With No Solid Prospects
May 09Despite Lacking Profits Precision BioSciences (NASDAQ:DTIL) Seems To Be On Top Of Its Debt
Apr 19Analyst Forecasts Just Became More Bearish On Precision BioSciences, Inc. (NASDAQ:DTIL)
Mar 21Precision BioSciences (NASDAQ:DTIL) Is Using Debt Safely
Dec 31Precision BioSciences: Uniquely Positioned
Oct 07Is Precision BioSciences (NASDAQ:DTIL) A Risky Investment?
Sep 24Precision BioSciences: The Right Profile To Progress
Aug 27Shareholder Returns
| DTIL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.2% | 0.07% | -0.2% |
| 1Y | -46.5% | 6.9% | 28.2% |
Return vs Industry: DTIL underperformed the US Biotechs industry which returned 5% over the past year.
Return vs Market: DTIL underperformed the US Market which returned 27.7% over the past year.
Price Volatility
| DTIL volatility | |
|---|---|
| DTIL Average Weekly Movement | 15.5% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DTIL's share price has been volatile over the past 3 months.
Volatility Over Time: DTIL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 109 | Michael Amoroso | www.precisionbiosciences.com |
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.
Precision BioSciences, Inc. Fundamentals Summary
| DTIL fundamental statistics | |
|---|---|
| Market cap | US$90.26m |
| Earnings (TTM) | -US$19.99m |
| Revenue (TTM) | US$57.53m |
1.6x
P/S Ratio-4.5x
P/E RatioIs DTIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DTIL income statement (TTM) | |
|---|---|
| Revenue | US$57.53m |
| Cost of Revenue | US$0 |
| Gross Profit | US$57.53m |
| Other Expenses | US$77.52m |
| Earnings | -US$19.99m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.89 |
| Gross Margin | 100.00% |
| Net Profit Margin | -34.74% |
| Debt/Equity Ratio | 60.4% |
How did DTIL perform over the long term?
See historical performance and comparison